Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on June 4)
Down In The Dumps
(Biotech stocks hitting 52-week lows on June 4)
Stock In Focus
Eli Lilly's Migraine Drug Notches Another FDA Approval
Rewalk's Robotic Stroke Therapy System Gets FDA Nod
Rewalk Robotics Ltd (NASDAQ:RWLK), which makes robotic medical devices for individuals with lower limb disabilities, said the FDA has approved its ReStore soft exo-suit system for sale to rehabilitation centers across the U.S.
The stock jumped 166.57 percent to $8.85 in pre-market trading.
On The Radar
Clinical Trial Readouts
Roche and AbbVie Inc (NYSE:ABBV) will present Phase 3 data for Venclexta plus Gazyva in chronic lympocytic leukemia at the ASCO 2019 annual meeting.
AnaptysBio Inc (NASDAQ:ANAB) is due to present Phase 2a data for ANB020 in severe adult eosinophilic asthma at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition 2019 annual meeting.
Related Links:
The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace
How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
